While the future of microbiome drug advancements looks bright, young startups may struggle to gain funding as investors aim to mitigate risk in the face of a wider unstable landscape.
Pharmabiotics: Young startups set for “hard time” in 2023 as investors look to de-risk
By 
Add A Comment